11 October 2016
The use of biomarkers and immunotherapy have been included in a new European curriculum for medical oncologists.
Translational research and personalised cancer medicine also get new chapters and sub-sections in the curriculum published by the European Society for Medical Oncology.
There is also a new section on genetic counselling.
Developers say the use of biomarkers as criteria to select therapies and the use of molecular pathology to detect them are now critical to oncology.
This "appreciable novelty" makes the curriculum a fundamental reference setting out internationally recognised standards for training oncologists, ESMO says.
Some 100 specialists have contributed to the curriculum, which has been endorsed already by 47 national oncology societies, including those of China, India, Germany and Sweden, but not by any in the UK.
ESMO President Fortunato Ciardiello said: “The release of the 2016 edition of the Global Curriculum highlights ESMO’s and ASCO’s commitment to supporting oncologists’ education worldwide so that they can further sharpen their expertise, adapt to the rapid changes in standards of practice, and learn how to collaborate effectively with other specialists in an integrated, multi-professional setting.”
Developer Dr Michael Kosty said: “The future of our specialty is in the hands of those who we are now training. To the degree we are able to establish a uniform, truly global curriculum, we will be helping patients the world over."
Disclaimer: The news stories shared on this site are used as a way to inform our members and followers of updates and relevant information happening in Haematology. The BSH does not endorse the content of news items from external sources, and is not in a position to verify the findings, accuracy or the source of any studies mentioned. Any medical or drugs information is provided as an information resource only, and is not to be relied on for any diagnostic or treatment purposes.